Source: Annual Congress 2003 - Asthma: potpourri
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. N. Krasnova, B. A. Tcherniak, A. A. Dzizinsky (Irkutsk, Russia). Efficacy and safety of b ₂ –agonists and ipratropium bromid in patients with bronchial asthma(BA) and ischemic heart disease (IHD). Eur Respir J 2003; 22: Suppl. 45, 2699

Member's Comments

No comment yet.

Related content which might interest you: Efficacy and safety of salmeterol in patients with bronchial asthma (BA) and ischemic heart disease (IHD) Source: Eur Respir J 2002; 20: Suppl. 38, 57s Year: 2002 Dose-dependent effects of salbutamol (S) and fenoterol (F) in patients with bronchial asthma (BA) and ischaemic heart disease (IHD) Source: Eur Respir J 2001; 18: Suppl. 33, 47s Year: 2001 Increased prevalence of obstructive airways disease (OAD) in patients with ischemic heart disease (IHD) and hypertension (HT) Source: Eur Respir J 2007; 30: Suppl. 51, 122s Year: 2007 Efficacy and tolerability of budesonide/formoterol (B/F) added to tiotropium (T) vs T alone in East-Asian patients (pts) with severe/very severe chronic obstructive pulmonary disease (COPD) Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Modelling the 5-year cost-effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease (COPD) in Spain Source: Eur Respir J 2006; 28: Suppl. 50, 683s Year: 2006 Effectiveness of vaccination of patients with combination of COPD and coronary heart disease (CHD) Source: International Congress 2015 – Different data in COPD Year: 2015 The ATTAIN study: Bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011 Do patients suffering from heart failure (HF) and chronic obstructive pulmonary disease (COPD) tolerate beta blocker (BB) treatment? Source: Annual Congress 2011 - Comorbidities and management in primary care Year: 2011 Safety of nebivolol and bisoprolol in patients (pts) with COPD and stable angina. Source: International Congress 2018 – Cardiovascular morbidities in COPD Year: 2018 Evaluation of the efficacy and safety of two formulations of Ipratropium bromide HFA pMDI in patients with mild to moderate chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2010 - COPD: treatment and monitoring Year: 2010 The beta-blockers in combined treatment of coronary heart disease in patients with chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2013 –COPD treatment Year: 2013 Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium Source: Eur Respir J 2002; 19: 209-216 Year: 2002 Use of intravenous (IV) aminophylline in acute exacerbations of COPD with decompensated acidotic type 2 respiratory failure (T2RF) requiring non-invasive ventilation (NIV) Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 Cardio- and cerebrovascular safety of QVA149 in patients with moderate-to-severe COPD: A pooled analysis Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Addition of tiotropium (T) to a regular treatment with long-acting β-agonist+inhaled corticosteroid (LABA+ICS) in patients with severe to very-severe COPD under in-patient pulmonary rehabilitation program (PRP) Source: Annual Congress 2009 - Pulmonary rehabilitation: extending the scope and benefit of rehabilitation for patients with chronic respiratory disease Year: 2009 Effects of acute dual bronchodilator treatment (tiotropium + olodaterol) on cardiopulmonary interactions in hyperinflated patients with COPD Source: International Congress 2018 – Advances in exercise physiopathology Year: 2018 Late-breaking abstract: HR-lowering efficacy and respiratory safety of ivabradine in patients with obstructive airway disease Source: Annual Congress 2011 - COPD: integrated care and rehabilitation Year: 2011 Effects of salmeterol on heart rate variability in patients with bronchial asthma and coronary artery disease Source: Annual Congress 2008 - Comorbid cardiovascular condition and therapy of asthma Year: 2008 Comparative study of one-year treatment with salmeterol along, and in combination with ipratropium bromide and beclometazone dipropionate in patients with chronic obstructi e pulmonary diseases (COPD) Source: Eur Respir J 2003; 22: Suppl. 45, 286s Year: 2003 Cardiovascular (CV) safety of indacaterol/glycopyrronium (IND/GLY) compared with salmeterol/fluticasone combination (SFC) in moderate-to-very severe COPD patients with prior exacerbations: The FLAME study Source: International Congress 2016 – Pharmacological management of COPD Year: 2016